Ionis Pharmaceuticals at AAPS 2026 PharmSci 360
Oct 25–28, 2026 New Orleans, LA ~4k attendees Website
Ionis Pharmaceuticals brings 3 presentations to AAPS 2026 PharmSci 360 in New Orleans. Its work centres on bioanalysis and clinical pharmacology for RNA-targeted drugs, including fixing plasma interference in an siRNA assay. Projects also cover measuring GFAP in an Alexander disease trial and the effect of liver impairment on olezarsen.
| Organization | AAPS 2026 PharmSci 360 Attendance |
|---|---|
Ionis Pharmaceuticals Carlsbad, CA | |
Develops RNA-targeted medicines, chiefly antisense oligonucleotides. | Poster Mon Oct 26 12:30pm–1:30pm Same Protein, Different siRNA: Hybridization-Driven Plasma Matrix Interference in an Intact hECL Assay Is Reversed by Hybridization Buffer and LNA Capture-Probe Optimization Poster Mon Oct 26 1:30pm–2:30pm Challenges in Analyzing GFAP in a Clinical Trial in Individuals with Alexander Disease Poster Wed Oct 28 9:30am–10:30am Phase 1 Evaluation of the Effect of Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Olezarsen |
Instantly find 20 buyers from Ionis Pharmaceuticals
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Association of Pharmaceutical Scientists (AAPS). Submit a correction